BCTX
BriaCell Therapeutics Corp.
There isn't enough reported data to score BCTX yet.
BCTX Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
BCTX's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
BCTX PE Valuation
BCTX has no meaningful PE right now: it lost money over the past year.
BCTX Forward outlook
There aren't enough analyst estimates for BCTX to show an outlook.
BCTX Earnings Per Share
BCTX Quarterly Revenue
BCTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2026 | -$8M | -$2M |
| Q4 2025 | -$7.7M | -$749.7K |
| Q2 2025 | -$7.2M | -$2.1M |
| Q1 2025 | -$5.9M | +$1.5M |
| Q4 2024 | -$7M | +$650.2K |
| Q2 2024 | -$5.1M | +$247.9K |
| Q1 2024 | -$7.4M | -$3.4M |
| Q4 2023 | -$7.6M | -$4.1M |
BCTX has burned cash in almost every quarter: −$29M over the past year, against −$25M the year before.
BCTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +159% | +4.4M shares |
| 1 year | +2586% | +7M shares |
| 3 years | +6908% | +7.1M shares |
BCTX has 7M diluted shares, up 2586% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $47,294 |
BCTX Net Leverage
BCTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BCTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 44.2 | Neutral |
| Stochastic | 37.2 | Neutral |
BCTX's weekly RSI is 44 (neutral) and its Stochastic is 37 (neutral).
BCTX PE vs Healthcare Sector
BCTX has no meaningful PE right now: it lost money over the past year.
BCTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.70 | 5.1% below |
| 20 week MA | $3.69 | 4.9% below |
| 50 week MA | $4.36 | 19% below |
| 100 week MA | $17.4 | 80% below |
| 200 week MA | $308.5 | 99% below |
BCTX is in a downtrend: it's below all five of its weekly moving averages, and 99% below its 200-week average.
BCTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,462.5 | $622.5 | -57% |
| 2021 | $622.5 | $1,395.0 | +124% |
| 2022 | $1,395.0 | $690.0 | -51% |
| 2023 | $690.0 | $877.5 | +27% |
| 2024 | $877.5 | $83.4 | -90% |
| 2025 | $83.4 | $7.74 | -91% |
| 2026 YTD | $7.74 | $3.51 | -55% |
BCTX's yearly returns have swung widely, from +124% in 2021 to −91% in 2025. It's down 55% so far in 2026.